Thoma Bravo’s Hudson Smith reveals how to pick winners amid the scramble for pharmaceutical dealmaking

The Covid-19 crisis has pushed what was already a healthy pharmaceutical investment market into overdrive, especially for tech and software-related deals. Fresh from his firm's buyout of clinical trial finance software provider Greenphire, Thoma Bravo partner Hudson Smith explained to AltAssets how to navigate the sector's high prices and where firms need to be aiming to get the best returns.